|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
FR2459619B1
(fr)
|
1979-06-26 |
1983-07-29 |
Agronomique Inst Nat Rech |
Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
|
|
US4350156A
(en)
|
1980-05-29 |
1982-09-21 |
Japan Foundation For Artificial Organs |
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
|
|
US4455256A
(en)
|
1981-05-05 |
1984-06-19 |
The Regents Of The University Of California |
Bone morphogenetic protein
|
|
EP0693946B1
(en)
|
1993-03-24 |
2001-05-16 |
Owen Mumford Limited |
Improvements relating to injection devices
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
|
DE19543737A1
(de)
|
1995-11-24 |
1997-05-28 |
Hoechst Ag |
Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL140592A0
(en)
|
1998-07-23 |
2002-02-10 |
Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
EP1115743B1
(en)
|
1998-09-25 |
2009-05-13 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
CA2355400A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co., Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
ZA200206457B
(en)
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
AU3846901A
(en)
|
2000-02-18 |
2001-08-27 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
AU2001275280B2
(en)
|
2000-06-05 |
2006-03-16 |
Teva Pharmaceutical Industries Ltd. |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
DE10158009A1
(de)
*
|
2001-11-21 |
2003-05-28 |
Begerow E Gmbh & Co |
Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen
|
|
AU2002353059B2
(en)
|
2001-12-04 |
2008-06-19 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
US7777006B2
(en)
|
2002-12-31 |
2010-08-17 |
Csl Behring L.L.C. |
Method for purification of alpha-1-antitrypsin
|
|
DK1592384T3
(da)
|
2003-01-21 |
2012-12-17 |
Yeda Res & Dev |
Cop 1 til behandling af inflammatoriske tarmsygdomme
|
|
WO2004091573A1
(en)
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PL1638589T3
(pl)
|
2003-05-14 |
2014-10-31 |
Teva Pharmaceutical Industries Ltd |
Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego
|
|
US8075919B2
(en)
|
2003-07-18 |
2011-12-13 |
Baxter International Inc. |
Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
|
|
AU2004285553B2
(en)
|
2003-10-31 |
2009-12-10 |
Teva Pharmaceutical Industries, Ltd. |
Nanoparticles for drug delivery
|
|
EP1701971A2
(en)
|
2003-12-31 |
2006-09-20 |
F.Hoffmann-La Roche Ag |
Peptide synthesis using decanting filter
|
|
WO2005084377A2
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
WO2006029036A2
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
US7495072B2
(en)
|
2004-09-09 |
2009-02-24 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
EP1797109B1
(en)
|
2004-09-09 |
2016-02-24 |
Yeda Research And Development Co., Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
|
JP5297653B2
(ja)
|
2004-10-29 |
2013-09-25 |
サンド・アクチエンゲゼルシヤフト |
グラチラマーの製造法
|
|
RU2419638C2
(ru)
|
2005-02-02 |
2011-05-27 |
Тева Фармасьютикал Индастриз, Лтд. |
Способ получения полипептидных смесей с использованием гидрогенолиза
|
|
CA2596664A1
(en)
|
2005-02-17 |
2006-08-24 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
WO2006116602A2
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
US20070059798A1
(en)
|
2005-09-09 |
2007-03-15 |
Alexander Gad |
Polypeptides useful for molecular weight determinations
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
AU2007269140A1
(en)
|
2006-07-05 |
2008-01-10 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
|
CN100569282C
(zh)
|
2006-10-13 |
2009-12-16 |
俞嘉林 |
注射用骨肽冻干剂及其制备方法
|
|
US8753833B2
(en)
|
2007-06-21 |
2014-06-17 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
CA2705046C
(en)
|
2007-07-31 |
2015-03-03 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
EP2111105A4
(en)
|
2007-11-28 |
2011-05-04 |
|
METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS
|
|
RU2469726C2
(ru)
|
2008-05-14 |
2012-12-20 |
Отономи, Инк. |
Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
|
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
CA2697570C
(en)
|
2009-07-15 |
2011-11-01 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
KR20140061559A
(ko)
|
2009-08-20 |
2014-05-21 |
에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 |
글라티라머 아세테이트를 포함하는 약제
|
|
ITMI20092069A1
(it)
|
2009-11-25 |
2011-05-26 |
Biofer Spa |
Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
WO2012051106A1
(en)
|
2010-10-11 |
2012-04-19 |
Teva Pharmaceutical Industries Ltd. |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
CA2827275A1
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
US8575198B1
(en)
*
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
TW201326399A
(zh)
|
2011-10-10 |
2013-07-01 |
Teva Pharma |
用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
|
|
CN104902974B
(zh)
*
|
2012-07-06 |
2017-07-28 |
三维矩阵有限公司 |
肽溶液的灌装加工法
|
|
TW201420111A
(zh)
|
2012-10-10 |
2014-06-01 |
Teva Pharma |
對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
|
|
EP2941274A4
(en)
|
2013-01-04 |
2016-11-16 |
Teva Pharma |
CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
AU2014248524A1
(en)
|
2013-03-12 |
2015-10-29 |
Teva Pharmaceutical Industries Ltd. |
Rituximab induction therapy followed by glatiramer acetate therapy
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|